pepcid- famotidine tablet, film coated
bausch health us llc - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 20 mg - pepcid tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: pepcid tablets are indicated in adults for the: reduction of the risk of duodenal ulcer recurrence. pepcid is contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other histamine-2 (h2) receptor antagonists. risk summary available data with h2-receptor antagonists, including famotidine, in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. in animal reproduction studies, no adverse development effects were observed with oral administration of famotidine at doses up to approximately 243 and 122 times, respectively, the recommended human dose of 80 mg per day for the treatment of erosive esophagitis (see data) . the estimated background risk for major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background ris
pepcid- famotidine powder, for suspension
salix pharmaceuticals, inc - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 40 mg in 5 ml - pepcid for oral suspension is indicated in adults for the treatment of: pepcid for oral suspension is indicated in pediatric patients 1 year of age and older for the treatment of: pepcid for oral suspension is indicated in pediatric patients from birth to less than 1 year of age for the treatment of: pepcid for oral suspension is contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other histamine-2 (h2) receptor antagonists. risk summary available data with h2-receptor antagonists, including famotidine, in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. in animal reproduction studies, no adverse development effects were observed with oral administration of famotidine at doses up to approximately 243 and 122 times, respectively, the recommended human dose of 80 mg per day for the treatment of erosive esophagitis (see data) . the estimated background ri
pepcid duo milligram tablets chewable
mcneil healthcare (ireland) ltd - famotidine, magnesium hydroxide, calcium carbonate - tablets chewable - milligram - h2-receptor antagonists
pepcidine
famotidine -
pepcid duo chewable tablets famotidine 10mg magnesium hydroxide 165mg calcium carbonate 800mg
johnson & johnson (ireland) limited - famotidine; magnesium hydroxide; calcium carbonate - chewable tablet - 10/165/800 milligram(s) - h2-receptor antagonists; famotidine, combinations
pepcid duo chewable tablets famotidine 10mg magnesium hydroxide 165mg calcium carbonate 800mg
jntl consumer health i (ireland) limited - famotidine; magnesium hydroxide; calcium carbonate - chewable tablet - h2-receptor antagonists; famotidine, combinations
pepcid 20 milligram film coated tablet
merck sharp and dohme limited - famotidine - film coated tablet - 20 milligram
pepcid 40 milligram film coated tablet
merck sharp and dohme limited - famotidine - film coated tablet - 40 milligram
pepcid ac film-coated 10 milligram film coated tablet
mcneil healthcare (ireland) ltd - famotidine - film coated tablet - 10 milligram - h2-receptor antagonists
pepcid ac 10 mg film-coated tablets
johnson & johnson (ireland) limited - famotidine - film-coated tablet - 10 milligram(s) - h2-receptor antagonists; famotidine